{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T13:14:09Z","timestamp":1774271649070,"version":"3.50.1"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Despite global vaccination efforts, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve and spread globally. Relatively high vaccination rates have been achieved in most regions of the United States and several countries worldwide. However, access to vaccines in low- and mid-income countries (LMICs) is still suboptimal. Second generation vaccines that are universally affordable and induce systemic and mucosal immunity are needed. Here we performed an extended safety and immunogenicity analysis of a second-generation SARS-CoV-2 vaccine consisting of a live Newcastle disease virus vector expressing a pre-fusion stabilized version of the spike protein (NDV-HXP-S) administered intranasally (IN), intramuscularly (IM), or IN followed by IM in Sprague Dawley rats. Local reactogenicity, systemic toxicity, and post-mortem histopathology were assessed after the vaccine administration, with no indication of severe local or systemic reactions. Immunogenicity studies showed that the three vaccination regimens tested elicited high antibody titers against the wild type SARS-CoV-2 spike protein and the NDV vector. Moreover, high antibody titers were induced against the spike of B.1.1.7 (alpha), B.1.351 (beta) and B.1.617.2 (delta) variants of concern (VOCs). Importantly, robust levels of serum antibodies with neutralizing activity against the authentic SARS-CoV-2 USA\u2010WA1\/2020 isolate were detected after the boost. Overall, our study expands the pre-clinical safety and immunogenicity characterization of NDV-HXP-S and reinforces previous findings in other animal models about its high immunogenicity. Clinical testing of this vaccination approach is ongoing in different countries including Thailand, Vietnam, Brazil and Mexico.<\/jats:p>","DOI":"10.3389\/fimmu.2021.791764","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T09:24:21Z","timestamp":1637227461000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats"],"prefix":"10.3389","volume":"12","author":[{"given":"Johnstone","family":"Tcheou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariel","family":"Raskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gagandeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisaaki","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominika","family":"Bielak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weina","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Gonz\u00e1lez-Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D Noah","family":"Sather","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adolfo","family":"Garc\u00eda-Sastre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Palese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Manuel","family":"Carre\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,18]]},"reference":[{"key":"B1","unstructured":"How to Protect Yourself & Others2021"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2036242","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"384","author":"Skowronski","year":"2021","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and Efficacy of Single-Dose Ad26 COV2 S Vaccine Against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"B5","unstructured":"FDA Approves First COVID-19 Vaccine2021"},{"key":"B6","unstructured":"Safety of COVID-19 Vaccines2021"},{"key":"B7","unstructured":"Coronavirus Disease (COVID-19): Vaccines Safety2021"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00790-X","article-title":"COVID-19 Vaccine Coverage in Health-Care Workers in England and Effectiveness of BNT162b2 mRNA Vaccine Against Infection (SIREN): A Prospective, Multicentre, Cohort Study","volume":"397","author":"Hall","year":"2021","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.15585\/mmwr.mm7013e3","article-title":"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021","volume":"70","author":"Thompson","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2107717","article-title":"Effect of Vaccination on Household Transmission of SARS-CoV-2 in England","volume":"385","author":"Harris","year":"2021","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7018e1","article-title":"Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged >\/=65 Years - United States, January-March 2021","volume":"70","author":"Tenforde","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2113017","article-title":"Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase","volume":"385","author":"El Sahly","year":"2021","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01316-7","article-title":"Initial Report of Decreased SARS-CoV-2 Viral Load After Inoculation With the BNT162b2 Vaccine","volume":"27","author":"Levine-Tiefenbrun","year":"2021","journal-title":"Nat Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc7520","article-title":"Isolation of Potent SARS-CoV-2 Neutralizing Antibodies and Protection From Disease in a Small Animal Model","volume":"369","author":"Rogers","year":"2020","journal-title":"Science"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1016\/j.cell.2021.06.005","article-title":"SARS-CoV-2 mRNA Vaccination Induces Functionally Diverse Antibodies to NTD, RBD, and S2","volume":"184","author":"Amanat","year":"2021","journal-title":"Cell"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/j.immuni.2021.08.001","article-title":"Rapid Induction of Antigen-Specific CD4(+) T Cells is Associated With Coordinated Humoral and Cellular Immunity to SARS-CoV-2 mRNA Vaccination","volume":"54","author":"Painter","year":"2021","journal-title":"Immunity"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1101\/2021.07.05.21259918","article-title":"Durable Humoral and Cellular Immune Responses Following Ad26.Cov2.S Vaccination for COVID-19","volume":"385","author":"Barouch","year":"2021","journal-title":"medRxiv"},{"key":"B18","doi-asserted-by":"publisher","first-page":"102620","DOI":"10.1016\/j.amsu.2021.102620","article-title":"Disparities in Global COVID-19 Vaccination Rates & Allocation of Resources to Countries in Need","volume":"68","author":"Sen-Crowe","year":"2021","journal-title":"Ann Med Surg (Lond)"},{"key":"B19","unstructured":"Tracking Coronavirus Vaccinations Around the World: The New York Times2021"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2108861","article-title":"Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients","volume":"385","author":"Kamar","year":"2021","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.7326\/L21-0282","article-title":"Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series","volume":"174","author":"Werbel","year":"2021","journal-title":"Ann Intern Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/0003-9861(68)90167-7","article-title":"Biosynthesis of Phosphatides of N-Ethyl Analogs of Choline In Vivo and In Vitro","volume":"123","author":"Bell","year":"1968","journal-title":"Arch Biochem Biophys"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1101\/2021.10.07.21264626","article-title":"Protection of BNT162b2 Vaccine Booster Against Covid-19 in Israel","volume":"385","author":"Bar-On","year":"2021","journal-title":"N Engl J Med"},{"key":"B24","unstructured":"Who Is Eligible for a COVID-19 Vaccine Booster Shot2021"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd2223","article-title":"IgA Dominates the Early Neutralizing Antibody Response to SARS-CoV-2","volume":"13","author":"Sterlin","year":"2021","journal-title":"Sci Transl Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 Vaccines in Development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e0190821","DOI":"10.1128\/mBio.01908-21","article-title":"Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX\/COVID-12-HEXAPRO (Patria), in Pigs","volume":"12","author":"Lara-Puente","year":"2021","journal-title":"mBio"},{"key":"B28","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3390\/vaccines8040771","article-title":"A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine","volume":"8","author":"Sun","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"103132","DOI":"10.1016\/j.ebiom.2020.103132","article-title":"Newcastle Disease Virus (NDV) Expressing the Spike Protein of SARS-CoV-2 as a Live Virus Vaccine Candidate","volume":"62","author":"Sun","year":"2020","journal-title":"EBioMedicine"},{"key":"B30","doi-asserted-by":"publisher","first-page":"6197","DOI":"10.1038\/s41467-021-26499-y","article-title":"A Newcastle Disease Virus Expressing a Stabilized Spike Protein of SARS-CoV-2 Induces Protective Immune Responses","volume":"12","author":"Sun","year":"2021","journal-title":"Nat Commun"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0913-5","article-title":"A Serological Assay to Detect SARS-CoV-2 Seroconversion in Humans","volume":"26","author":"Amanat","year":"2020","journal-title":"Nat Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1371\/journal.pmed.0030237","article-title":"Human Monoclonal Antibody Combination Against SARS Coronavirus: Synergy and Coverage of Escape Mutants","volume":"3","author":"ter Meulen","year":"2006","journal-title":"PloS Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1002\/cpmc.108","article-title":"An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening","volume":"58","author":"Amanat","year":"2020","journal-title":"Curr Protoc Microbiol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-020-00547-5","article-title":"Cold Sensitivity of the SARS-CoV-2 Spike Ectodomain","volume":"28","author":"Edwards","year":"2021","journal-title":"Nat Struct Mol Biol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3909743","article-title":"Effectiveness of mRNA BNT162b2 COVID-19 Vaccine Up to 6 Months in a Large Integrated Health System in the USA: A Retrospective Cohort Study","volume":"398","author":"Tartof","year":"2021","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","first-page":"S1198-743X(21)00465-1","DOI":"10.1016\/j.cmi.2021.08.008","article-title":"Mucosal Immunity to SARS-CoV-2: A Clinically Relevant Key to Deciphering Natural and Vaccine-Induced Defences","author":"Matuchansky","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"B37","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3390\/v8070183","article-title":"Newcastle Disease Virus as a Vaccine Vector for Development of Human and Veterinary Vaccines","volume":"8","author":"Kim","year":"2016","journal-title":"Viruses"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2012.06.001","article-title":"Newcastle Disease Virus-Vectored Nipah Encephalitis Vaccines Induce B and T Cell Responses in Mice and Long-Lasting Neutralizing Antibodies in Pigs","volume":"432","author":"Kong","year":"2012","journal-title":"Virology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"108490","DOI":"10.1016\/j.vetmic.2019.108490","article-title":"Construction and Immunological Evaluation of Recombinant Newcastle Disease Virus Vaccines Expressing Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Virus GP3\/GP5 Proteins in Pigs","volume":"239","author":"Zhang","year":"2019","journal-title":"Vet Microbiol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-019-04425-4","article-title":"Evaluation of Surface Glycoproteins of Classical Swine Fever Virus as Immunogens and Reagents for Serological Diagnosis of Infections in Pigs: A Recombinant Newcastle Disease Virus Approach","volume":"164","author":"Kumar","year":"2019","journal-title":"Arch Virol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1101\/2021.09.17.21263758","article-title":"Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1\/2 Trial","author":"Pitisuttithum","year":"2021","journal-title":"medRxiv"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1177\/1091581810391818","article-title":"Differences in Rat Models Used in Routine Toxicity Studies","volume":"30","author":"Weber","year":"2011","journal-title":"Int J Toxicol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690761","article-title":"Evaluation of Rodent-Only Toxicology for Early Clinical Trials With Novel Cancer Therapeutics","volume":"81","author":"Newell","year":"1999","journal-title":"Br J Cancer"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e20008","DOI":"10.1371\/journal.pone.0020008","article-title":"Study of Histopathological and Molecular Changes of Rat Kidney Under Simulated Weightlessness and Resistance Training Protective Effect","volume":"6","author":"Ding","year":"2011","journal-title":"PloS One"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/jat.935","article-title":"Histopathological and Biochemical Changes in Lung Tissues of Rats Following Administration of Fluoride Over Several Generations","volume":"23","author":"Aydin","year":"2003","journal-title":"J Appl Toxicol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s00580-013-1818-1","article-title":"Influence of Zinc Supplementation on Histopathological Changes in the Stomach, Liver, Kidney, Brain, Pancreas and Spleen During Subchronic Exposure of Wistar Rats to Glyphosate","volume":"23","author":"Tizhe","year":"2014","journal-title":"Comp Clin Path"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.791764\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T09:24:26Z","timestamp":1637227466000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.791764\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":46,"alternative-id":["10.3389\/fimmu.2021.791764"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.791764","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,18]]},"article-number":"791764"}}